Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Evans

Showing results (601-610 of 621) with videos related to

Pageof 63
Sort By:
NPJ Breast Cancer|January 14, 2022
The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situDaniela Nachmanson, Adam Officer, Hidetoshi Mori, et al.
Bioorganic & Medicinal Chemistry Letters|July 18, 2009
Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitisBrian A Stearns, Christopher Baccei, Gretchen Bain, et al.
Journal of Medicinal Chemistry|November 9, 2011
5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitorNicholas S Stock, Gretchen Bain, Jasmine Zunic, et al.
Journal of Medicinal Chemistry|May 5, 2017
Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2)Martin W Rowbottom, Gretchen Bain, Imelda Calderon, et al.
Leukemia|May 4, 2012
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideA Lopez-Girona, D Mendy, T Ito, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 10, 2009
Pharmacological blockade of the DP2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia, and epithelial hyperplasia in the mouse lungKarin J Stebbins, Alex R Broadhead, Christopher S Baccei, et al.
Clinical Pharmacology and Therapeutics|February 26, 2010
Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP)G Bain, C D King, M Rewolinski, et al.
European Journal of Pharmacology|June 4, 2010
Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammationDaniel S Lorrain, Gretchen Bain, Lucia D Correa, et al.
International Journal of Epidemiology|March 25, 2017
Mammographic density defined by higher than conventional brightness thresholds better predicts breast cancer riskTuong L Nguyen, Ye K Aung, Christopher F Evans, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 17, 2010
Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonistJ S Swaney, C Chapman, L D Correa, et al.
Pageof 63

Showing results (601-610 of 621) with videos related to

Sort By:
Pageof 63
NPJ Breast Cancer|January 14, 2022
The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situDaniela Nachmanson, Adam Officer, Hidetoshi Mori, et al.
Bioorganic & Medicinal Chemistry Letters|July 18, 2009
Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitisBrian A Stearns, Christopher Baccei, Gretchen Bain, et al.
Journal of Medicinal Chemistry|November 9, 2011
5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitorNicholas S Stock, Gretchen Bain, Jasmine Zunic, et al.
Journal of Medicinal Chemistry|May 5, 2017
Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2)Martin W Rowbottom, Gretchen Bain, Imelda Calderon, et al.
Leukemia|May 4, 2012
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideA Lopez-Girona, D Mendy, T Ito, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 10, 2009
Pharmacological blockade of the DP2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia, and epithelial hyperplasia in the mouse lungKarin J Stebbins, Alex R Broadhead, Christopher S Baccei, et al.
Clinical Pharmacology and Therapeutics|February 26, 2010
Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP)G Bain, C D King, M Rewolinski, et al.
European Journal of Pharmacology|June 4, 2010
Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammationDaniel S Lorrain, Gretchen Bain, Lucia D Correa, et al.
International Journal of Epidemiology|March 25, 2017
Mammographic density defined by higher than conventional brightness thresholds better predicts breast cancer riskTuong L Nguyen, Ye K Aung, Christopher F Evans, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 17, 2010
Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonistJ S Swaney, C Chapman, L D Correa, et al.
Pageof 63